Brief: Bluejay Diagnostics- Testing Program Underway For Lead Product Candidate, Symphony Il-6 Test, In Support Of FDA Marketing Application, Planned For Q3 2022
10/03/2022 11:42
March 10 (Reuters) - Bluejay Diagnostics Inc BJDX.O :
* BLUEJAY DIAGNOSTICS- TESTING PROGRAM UNDERWAY FOR LEAD
PRODUCT
CANDIDATE, SYMPHONY IL-6 TEST, IN SUPPORT OF FDA MARKETING
APPLICATION, PLANNED FOR Q3 2022
* BLUEJAY DIAGNOSTICS INC- CASH AND CASH EQUIVALENTS ON
DECEMBER
31, 2021 WERE $19,047,778
* BLUEJAY DIAGNOSTICS INC- NET LOSS PER SHARE FOR THE THREE
MONTHS
ENDED DECEMBER 31, 2021 WAS $0.09
Source: [https://bit.ly/3vVsfq8]
Further company coverage: BJDX.O
Recent news on Bluejay Diagnostics
See all newsBrief: Bluejay Diagnostics Announces Successful Completion Of Enrollment In The Symon-II Multicenter Clinical Validation Study
Brief: Bluejay Diagnostics And Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Q1 net loss unchanged
Brief: Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial
Brief: Bluejay Diagnostics Provides Corporate Update And 2026 Strategic Outlook